MY177820A - Controlled release peptide formulations - Google Patents
Controlled release peptide formulationsInfo
- Publication number
- MY177820A MY177820A MYPI2013004227A MYPI2013004227A MY177820A MY 177820 A MY177820 A MY 177820A MY PI2013004227 A MYPI2013004227 A MY PI2013004227A MY PI2013004227 A MYPI2013004227 A MY PI2013004227A MY 177820 A MY177820 A MY 177820A
- Authority
- MY
- Malaysia
- Prior art keywords
- controlled release
- compositions
- forming
- peptide formulations
- release peptide
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 6
- 238000009472 formulation Methods 0.000 title abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 238000013270 controlled release Methods 0.000 title 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 abstract 2
- 239000013543 active substance Substances 0.000 abstract 1
- 239000003963 antioxidant agent Substances 0.000 abstract 1
- 230000003078 antioxidant effect Effects 0.000 abstract 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 abstract 1
- 150000001982 diacylglycerols Chemical class 0.000 abstract 1
- 239000012530 fluid Substances 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000002798 polar solvent Substances 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
- 229960001295 tocopherol Drugs 0.000 abstract 1
- 229930003799 tocopherol Natural products 0.000 abstract 1
- 235000010384 tocopherol Nutrition 0.000 abstract 1
- 239000011732 tocopherol Substances 0.000 abstract 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/31—Somatostatins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases or cochleates; Sponge phases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/655—Somatostatins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161489886P | 2011-05-25 | 2011-05-25 | |
| PCT/EP2012/059917 WO2012160213A1 (en) | 2011-05-25 | 2012-05-25 | Controlled release peptide formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY177820A true MY177820A (en) | 2020-09-23 |
Family
ID=46456496
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2013004227A MY177820A (en) | 2011-05-25 | 2012-05-25 | Controlled release peptide formulations |
Country Status (37)
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8236292B2 (en) * | 2004-06-04 | 2012-08-07 | Camurus Ab | Liquid depot formulations |
| JP6375289B2 (ja) | 2012-04-05 | 2018-08-15 | マサチューセッツ インスティテュート オブ テクノロジー | 免疫刺激組成物およびその使用方法 |
| BR112014029425A2 (pt) * | 2012-05-25 | 2017-06-27 | Camurus Ab | pré-formulação, dispositivo de administração pré-cheio, kit, processo para a formação de uma pré-formulação, usos de mistura e de um solvente polar, e, método para o tratamento de um sujeito |
| HRP20210068T1 (hr) | 2012-07-26 | 2021-03-05 | Camurus Ab | Opioidne formulacije |
| WO2014016428A1 (en) | 2012-07-26 | 2014-01-30 | Camurus Ab | Opioid formulations |
| US10300145B2 (en) | 2016-07-15 | 2019-05-28 | Massachusetts Institute Of Technology | Synthetic nanoparticles for delivery of immunomodulatory compounds |
| RU2757903C2 (ru) | 2016-09-15 | 2021-10-22 | Камурус Аб | Препараты аналогов простациклина |
| MX383392B (es) | 2016-09-27 | 2025-03-13 | Camurus Ab | Mezclas y formulaciones que comprenden una sal de alquil amonio de ácido etilendiaminotetraacético (edta). |
| KR20190093196A (ko) | 2016-12-07 | 2019-08-08 | 라 파마슈티컬스 인코포레이티드 | 보체 활성의 조절인자 |
| JP7710707B2 (ja) * | 2017-11-15 | 2025-07-22 | リズム ファーマシューティカルズ， インコーポレイテッド | 持続放出ペプチド製剤 |
| MA52434A (fr) | 2018-03-02 | 2021-01-06 | Elicio Therapeutics Inc | Amphiphiles cpg et leurs utilisations |
| CN109091451B (zh) * | 2018-09-10 | 2021-08-13 | 武汉百纳礼康生物制药有限公司 | 亲水性药物的油相液晶凝胶前体制剂及其制备方法 |
| WO2020191305A2 (en) | 2019-03-20 | 2020-09-24 | Massachusetts Institute Of Technology | Uses of amphiphiles in immune cell therapy and compositions therefor |
| MX2021014450A (es) | 2019-05-29 | 2022-01-06 | Camurus Ab | Composiciones de liberacion controlada de lipidos. |
| CN113368041B (zh) * | 2020-07-17 | 2023-01-03 | 丽珠医药集团股份有限公司 | 药物组合物、缓释制剂及其制备方法 |
| IL308133A (en) * | 2021-05-04 | 2023-12-01 | Camurus Ab | Compositions and methods for treating neuroendocrine tumors |
| EP4731247A1 (en) * | 2023-06-20 | 2026-04-29 | Camurus AB | Compositions and methods for treating acromegaly |
| WO2025229402A1 (en) | 2024-05-02 | 2025-11-06 | Camurus Ab | Lipid compositions and methods of use thereof |
| WO2025229403A1 (en) | 2024-05-02 | 2025-11-06 | Camurus Ab | Lipid compositions and methods of use thereof |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006075124A1 (en) * | 2005-01-14 | 2006-07-20 | Camurus Ab | Somatostatin analogue formulations |
| PL1682091T3 (pl) * | 2003-11-07 | 2017-09-29 | Camurus Ab | Kompozycje lipidów i kationowych peptydów |
| GB0412530D0 (en) * | 2004-06-04 | 2004-07-07 | Camurus Ab | Formulation |
| US8236292B2 (en) * | 2004-06-04 | 2012-08-07 | Camurus Ab | Liquid depot formulations |
| PL1778187T3 (pl) | 2004-08-04 | 2012-09-28 | Camurus Ab | Kompozycje tworzące nielamelarne dyspersje |
| GB0417388D0 (en) | 2004-08-04 | 2004-09-08 | Camurus Ab | Composition |
| EP1843746B1 (en) * | 2005-01-14 | 2011-03-16 | Camurus Ab | Somatostatin analogue formulations |
| US9757461B2 (en) * | 2005-01-14 | 2017-09-12 | Camurus Ab | GnRH analogue formulations |
| KR101245022B1 (ko) * | 2005-01-21 | 2013-03-19 | 카무러스 에이비 | 약제학적 지질 조성물 |
| US20080200383A1 (en) * | 2005-04-08 | 2008-08-21 | Amylin Pharmaceuticals, Inc. | Pharmaceutical Formulations Comprising Incretin Peptide and Aprotic Polar Solvent |
| US8097239B2 (en) * | 2005-06-06 | 2012-01-17 | Camurus Ab | Controlled-release formulations |
| EP1888031B1 (en) * | 2005-06-06 | 2013-01-23 | Camurus Ab | Glp-1 analogue formulations |
| GB0711656D0 (en) * | 2007-06-15 | 2007-07-25 | Camurus Ab | Formulations |
| GB0716385D0 (en) * | 2007-08-22 | 2007-10-03 | Camurus Ab | Formulations |
| GB0815435D0 (en) * | 2008-08-22 | 2008-10-01 | Camurus Ab | Formulations |
| US8931272B2 (en) * | 2010-10-29 | 2015-01-13 | Ford Global Technologies, Llc | Method and system for limiting output of a boosted engine |
| MX350929B (es) * | 2011-12-05 | 2017-09-26 | Camurus Ab | Formulaciones peptidicas robustas de liberación controlada. |
| BR112014029425A2 (pt) * | 2012-05-25 | 2017-06-27 | Camurus Ab | pré-formulação, dispositivo de administração pré-cheio, kit, processo para a formação de uma pré-formulação, usos de mistura e de um solvente polar, e, método para o tratamento de um sujeito |
| US20230285502A1 (en) * | 2016-09-07 | 2023-09-14 | Camurus Ab | Mixtures and formulations |
| MX383392B (es) * | 2016-09-27 | 2025-03-13 | Camurus Ab | Mezclas y formulaciones que comprenden una sal de alquil amonio de ácido etilendiaminotetraacético (edta). |
-
2012
- 2012-05-25 CN CN201280025151.1A patent/CN103702662B/zh active Active
- 2012-05-25 SG SG2013083019A patent/SG194865A1/en unknown
- 2012-05-25 HR HRP20240781TT patent/HRP20240781T1/hr unknown
- 2012-05-25 AU AU2012260821A patent/AU2012260821B2/en active Active
- 2012-05-25 BR BR112013030104A patent/BR112013030104A8/pt not_active Application Discontinuation
- 2012-05-25 CA CA2836847A patent/CA2836847C/en active Active
- 2012-05-25 SI SI201232066T patent/SI2714004T1/sl unknown
- 2012-05-25 WO PCT/EP2012/059917 patent/WO2012160213A1/en not_active Ceased
- 2012-05-25 TW TW101118843A patent/TWI624271B/zh active
- 2012-05-25 FI FIEP12731315.3T patent/FI2714004T3/fi active
- 2012-05-25 MY MYPI2013004227A patent/MY177820A/en unknown
- 2012-05-25 EA EA201391675A patent/EA036213B1/ru not_active IP Right Cessation
- 2012-05-25 ES ES12731315T patent/ES2984717T3/es active Active
- 2012-05-25 EP EP24175676.6A patent/EP4427814A3/en active Pending
- 2012-05-25 PT PT127313153T patent/PT2714004T/pt unknown
- 2012-05-25 KR KR1020137034307A patent/KR102066755B1/ko active Active
- 2012-05-25 JP JP2014511911A patent/JP6265888B2/ja active Active
- 2012-05-25 LT LTEPPCT/EP2012/059917T patent/LT2714004T/lt unknown
- 2012-05-25 EP EP12731315.3A patent/EP2714004B1/en active Active
- 2012-05-25 RS RS20240722A patent/RS65702B1/sr unknown
- 2012-05-25 US US14/117,994 patent/US11433120B2/en active Active
- 2012-05-25 PL PL12731315.3T patent/PL2714004T3/pl unknown
- 2012-05-25 CN CN201810174910.XA patent/CN108283619B/zh active Active
- 2012-05-25 MX MX2013013401A patent/MX361716B/es active IP Right Grant
- 2012-05-25 PE PE2013002546A patent/PE20141484A1/es active IP Right Grant
- 2012-05-25 HU HUE12731315A patent/HUE067389T2/hu unknown
- 2012-05-25 DK DK12731315.3T patent/DK2714004T3/da active
- 2012-05-28 AR ARP120101869A patent/AR086577A1/es unknown
-
2013
- 2013-11-11 IL IL22937613A patent/IL229376B/en active IP Right Grant
- 2013-11-22 DO DO2013000275A patent/DOP2013000275A/es unknown
- 2013-11-22 CL CL2013003365A patent/CL2013003365A1/es unknown
- 2013-11-22 NI NI201300127A patent/NI201300127A/es unknown
- 2013-11-22 GT GT201300292A patent/GT201300292A/es unknown
- 2013-11-25 CU CU2013000158A patent/CU20130158A7/es unknown
- 2013-12-09 PH PH12013502550A patent/PH12013502550B1/en unknown
- 2013-12-12 CR CR20130653A patent/CR20130653A/es unknown
- 2013-12-20 CO CO13297046A patent/CO6900117A2/es unknown
- 2013-12-20 ZA ZA2013/09653A patent/ZA201309653B/en unknown
- 2013-12-24 EC ECSP13013107 patent/ECSP13013107A/es unknown
-
2016
- 2016-04-06 AU AU2016202156A patent/AU2016202156B2/en active Active
-
2017
- 2017-11-29 JP JP2017228735A patent/JP6415673B2/ja active Active
-
2021
- 2021-06-17 US US17/350,363 patent/US20210308226A1/en not_active Abandoned
-
2024
- 2024-09-18 US US18/889,001 patent/US20250121035A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY177820A (en) | Controlled release peptide formulations | |
| MX352024B (es) | Formulaciones potentes de liberacion controlada. | |
| AR083016A1 (es) | Formulaciones liquidas para la agricultura con una mejor estabilidad | |
| BR112012006686B8 (pt) | compostos de amida substituída, composições farmacêuticas contendo os ditos compostos, e uso dos mesmos para prevenir e/ou tratar doenças causadas pelo lpa | |
| MX2018003333A (es) | Formulaciones de liberacion controlada. | |
| MX2013002830A (es) | Composicion que contiene un insecticida de piripiropeno y un adyuvante. | |
| EA201791166A1 (ru) | Препараты с контролируемым высвобождением | |
| BR112013028531A2 (pt) | composição inseticida líquida | |
| TN2014000483A1 (en) | Somatostatin receptor agonist formulations | |
| ATE501710T1 (de) | Somatostatin-analog-formulierungen | |
| AR086045A1 (es) | Componente de formulacion | |
| EA201201480A1 (ru) | Адгезионные ретардированные составы для местного применения куркумина | |
| MX362592B (es) | Supresion de olor de los compuestos analgesicos organicos volatiles y metodo de uso. | |
| HK1239563A1 (en) | Controlled-release formulations | |
| TH1301006692A (th) | สูตรผสมเปปไทด์ที่ปลดปล่อยยาในอัตราคงที่ | |
| IN2013MU03800A (https=) | ||
| BR112018001637A2 (pt) | concentrado contendo alprostadil |